UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Long road towards effective HER3 targeting in breast cancer

Cancer treatment reviews, 2024-09, Vol.129, p.102786, Article 102786

2024

Volltextzugriff (PDF)

Genomic alterations of ERBB receptors in cancer: clinical implications

Oncotarget, 2017-12, Vol.8 (69), p.114371-114392

2017

Volltextzugriff (PDF)

Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade

Cancer cell, 2018-05, Vol.33 (5), p.922-936.e10

2018

Volltextzugriff (PDF)

The HER family as therapeutic targets in colorectal cancer

Critical reviews in oncology/hematology, 2022-06, Vol.174, p.103681-103681, Article 103681

2022

Volltextzugriff (PDF)

Clinical development of HER3-targeting monoclonal antibodies: Perils and progress

Cancer treatment reviews, 2018-07, Vol.68, p.111-123

2018

Volltextzugriff (PDF)

Role of human epidermal growth factor receptor 3 in treatment resistance of anaplastic lymphoma kinase translocated non-small cell lung cancer

Cancer biology & therapy, 2023-12, Vol.24 (1), p.2256906-2256906

2023

Volltextzugriff (PDF)

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

Frontiers in oncology, 2016-10, Vol.6, p.232-232

2016

Volltextzugriff (PDF)

Her3-specific affibody mediated tumor targeting delivery of ICG enhanced the photothermal therapy against Her3-positive tumors

International journal of pharmaceutics, 2022-04, Vol.617, p.121609-121609, Article 121609

2022

Volltextzugriff (PDF)

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild‐Type Non‐Small Cell Lung Cancer

The oncologist (Dayton, Ohio), 2019-08, Vol.24 (8), p.1095-1102

2019

Volltextzugriff (PDF)

NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells

International journal of oncology, 2017-11, Vol.51 (5), p.1553-1562

2017

Volltextzugriff (PDF)

Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors

Investigational new drugs, 2021-12, Vol.39 (6), p.1604-1612

2021

Volltextzugriff (PDF)

AMPK activation attenuates HER3 upregulation and Neuregulin-Mediated rescue of cell proliferation in HER2-Overexpressing breast cancer cell lines exposed to lapatinib

Biochemical pharmacology, 2022-10, Vol.204, p.115228-115228, Article 115228

2022

Volltextzugriff (PDF)

Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review

European journal of pharmacology, 2024-08, Vol.977, p.176725, Article 176725

2024

Volltextzugriff (PDF)

Corosolic acid inhibits colorectal cancer cells growth as a novel HER2/HER3 heterodimerization inhibitor

British journal of pharmacology, 2021-03, Vol.178 (6), p.1475-1491

2021

Volltextzugriff (PDF)

HER3 in cancer: from the bench to the bedside

Journal of experimental & clinical cancer research, 2022-10, Vol.41 (1), p.1-310, Article 310

2022

Volltextzugriff (PDF)

A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer

Oncotarget, 2017-10, Vol.8 (51), p.89284-89306

2017

Volltextzugriff (PDF)

HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?

Cancer and metastasis reviews, 2017-03, Vol.36 (1), p.141-157

2017

Volltextzugriff (PDF)

Beyond HER2: Targeting the ErbB receptor family in breast cancer

Cancer treatment reviews, 2022-09, Vol.109, p.102436-102436, Article 102436

2022

Volltextzugriff (PDF)

Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI–B001, an EGFR/HER3 Bi-specific Monoclonal Antibody

Journal of pharmaceutical sciences, 2020-10, Vol.109 (10), p.3172-3180

2020

Volltextzugriff (PDF)

Ultrasensitive electrochemical detection of cancer associated biomarker HER3 based on anti-HER3 biosensor

Talanta (Oxford), 2014-03, Vol.120, p.355-361

2014

Volltextzugriff (PDF)

Adding of neurotensin to non-small cell lung cancer cells increases tyrosine phosphorylation of HER3

Peptides (New York, N.Y. : 1980), 2022-10, Vol.156, p.170858-170858, Article 170858

2022

Volltextzugriff (PDF)

Pathogenic HER3 dimerization domain mutations create a structural bias towards un-conventional EGFR-HER3 signalling axis in breast cancer

International journal of biological macromolecules, 2023-07, Vol.242 (Pt 2), p.124765-124765, Article 124765

2023

Volltextzugriff (PDF)

Antibody Drug Conjugates in Lung Cancer

The cancer journal (Sudbury, Mass.), 2022-11, Vol.28 (6), p.429-435

2022

Volltextzugriff (PDF)

Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity

Cancer cell, 2021-08, Vol.39 (8), p.1099-1114.e8

2021

Volltextzugriff (PDF)

1 – 25 von 394

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(347)
Mit Volltextzugriff
(361)

Publikationsform

Artikel
(392)
Buchkapitel
(2)

Sprache

Englisch
(394)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Long road towards effective HER3 targeting in breast cancer

Genomic alterations of ERBB receptors in cancer: clinical implications

Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade

The HER family as therapeutic targets in colorectal cancer

Clinical development of HER3-targeting monoclonal antibodies: Perils and progress

Role of human epidermal growth factor receptor 3 in treatment resistance of anaplastic lymphoma kinase translocated non-small cell lung cancer

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

Her3-specific affibody mediated tumor targeting delivery of ICG enhanced the photothermal therapy against Her3-positive tumors

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild‐Type Non‐Small Cell Lung Cancer

NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells

Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors

AMPK activation attenuates HER3 upregulation and Neuregulin-Mediated rescue of cell proliferation in HER2-Overexpressing breast cancer cell lines exposed to lapatinib

Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review

Corosolic acid inhibits colorectal cancer cells growth as a novel HER2/HER3 heterodimerization inhibitor

HER3 in cancer: from the bench to the bedside

A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer

HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?

Beyond HER2: Targeting the ErbB receptor family in breast cancer

Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI–B001, an EGFR/HER3 Bi-specific Monoclonal Antibody

Ultrasensitive electrochemical detection of cancer associated biomarker HER3 based on anti-HER3 biosensor

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer

Adding of neurotensin to non-small cell lung cancer cells increases tyrosine phosphorylation of HER3

Pathogenic HER3 dimerization domain mutations create a structural bias towards un-conventional EGFR-HER3 signalling axis in breast cancer

Antibody Drug Conjugates in Lung Cancer

Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity

Aktive Filter

Suchergebnisse filtern